Open AccessDeutetrabenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication—What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Author(s) -
Citrome Leslie
Publication year - 2017
Publication title -
international journal of clinical practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.756
H-Index - 98
eISSN - 1742-1241
pISSN - 1368-5031
DOI - 10.1111/ijcp.13030
Subject(s) - medicine , tolerability , tetrabenazine , clinical trial , placebo , tardive dyskinesia , medline , alternative medicine , psychiatry , adverse effect , pharmacology , schizophrenia (object oriented programming) , pathology , political science , law , dopamine
Deutetrabenazine is a deuterated formulation of tetrabenazine. The aim of this systematic review is to describe the efficacy, tolerability and safety of deutetrabenazine for the treatment of tardive dyskinesia (TD).